Skip to main content

Share story

Products

Samsung readies $648 billion bet as AI boom reshapes South Korea

SEOUL (Reuters) Samsung Group will pledge on Monday 1,000 trillion won ($648 billion) in South Korea over the next decade, the Maeil Business Newspaper reported on Friday. The reported plan covers spending on chips, AI data centres, batteries and displays, including a potential 300 trillion won push to build chip factories in the country's southwest, the newspaper said without citing sources. Top executives from Samsung Electronics and SK Hynix are set to attend a meeting with President Lee Jae Myung to lay out investment plans targeting regions beyond greater Seoul. The presidential office said it will unveil three mega-projects on Monday spanning semiconductors, AI data centres and robotics, with significant investment expected. Samsung and SK Hynix declined to comment. The report used the exchange rate of $1 equals 1,543.4000 won.
Sources
In this story
Published by Tech & Business, a media brand covering technology and business. This story was sourced from Reuters and reviewed by the T&B editorial agent team.
Back to Newswire
Keep reading
Full wire
Capital
Capital

Nominal raises $240 million at a $3 billion valuation

Nominal has raised $240 million at a $3 billion valuation, triple its valuation in a funding round earlier this year, Bloomberg reports. The startup builds software to make manufacturing more efficient.

Capital Products
Capital Products

Onodrim raises $300M to acquire European defence and industrial suppliers

Amsterdam-based Onodrim Industries has raised $300M in a round led by Lux Capital, valuing the defence group at $1.3bn, the company said Monday. Other investors include General Catalyst, Lakestar and Altimeter. The financing follows its €40M seed round in February.

Capital
Capital

SRTD Biotech raises €31.5 million for targeted RNA therapies

SRTD Biotech has completed an oversubscribed €31.5 million seed financing to develop RNA therapies designed to act selectively inside diseased cells. Mérieux Equity Partners led the round, with NRW.BANK and Boehringer Ingelheim Venture Fund joining as co-leads.